FDA, Rx Antihistamine Makers' Next Move: Compromise?
This article was originally published in The Tan Sheet
Executive Summary
A negotiated compromise between FDA and the manufacturers of second-generation antihistamines seems the most logical way to resolve the legal, regulatory and financial obstacles facing both sides.
You may also be interested in...
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec